The Victorian Government has signed a landmark international Partnership Agreement between the Shanghai Institute of Medical Quality and the Melbourne Biomedical Precinct.
With a major focus on cancer treatment, the agreement will open up new opportunities for Victorian companies, universities and research institutes, generate more jobs for Victorians in the pharmaceutical, medical and biotechnology sectors, and enable the sharing of expertise in healthcare and patient safety.
Located in Parkville (on the edge of Melbourne's city centre), the Melbourne Biomedical Precinct is one of the world's largest life science research clusters and has established itself as a leading global research and teaching powerhouse. Sharing a remarkable history of ground-breaking medical discoveries and developments, precinct partners include the Victorian Comprehensive Cancer Centre, the Peter MacCullum Cancer Centre, the University of Melbourne and Melbourne Health (through the Royal Melbourne Hospital ).
As part of the agreement, an annual training program to advance patient treatment outcomes will be led by Melbourne Biomedical Precinct partners, and from October 2017, Chinese medical practitioners, senior nurses and hospital executives will visit Melbourne to receive training in healthcare including cancer treatment, new technologies and hospital management tools.
Victoria's reputation in pharmaceutical development and manufacturing is world-class and presents enormous potential for Chinese investment and commercialisation of Victorian products and medicines.
Melbourne is home to more than half of Australia's ASX-listed life science companies and two of the top five biomedical universities in the Asia-Pacific region – the University of Melbourne and Monash University.